Boston Scientific Corporation's Stock Analysis

Boston Scientific Announces Merger Agreement with Penumbra, Inc.

Boston Scientific Corporation has entered into a Merger Agreement with Penumbra, Inc. that will result in Penumbra becoming a wholly owned subsidiary of Boston Scientific. Under the terms of the agreement, Penumbra shareholders will have the option to receive either cash or shares of Boston Scientific stock in exchange for their shares, with specific proration mechanisms in place for the elections. The merger is contingent upon several conditions, including the approval of Penumbra's stockholders and various regulatory approvals.

The agreement includes provisions that restrict Penumbra from soliciting other acquisition proposals and outlines termination fees for both parties. If Penumbra terminates the agreement to pursue a superior proposal, it will owe Boston Scientific a fee of $525 million, while Boston Scientific will owe Penumbra $900 million if the merger is terminated under certain conditions. The completion of the merger is subject to meeting all specified conditions outlined in the agreement.

Jan 15, 2026 17:05:37

Boston Scientific to Acquire Penumbra for $14.5 Billion

Boston Scientific Corporation has announced a definitive agreement to acquire Penumbra, Inc. in a transaction valued at approximately $14.5 billion, or $374 per share. The acquisition aims to enhance Boston Scientific's portfolio in the cardiovascular segment and expand its offerings in mechanical thrombectomy and neurovascular solutions. The deal is structured to provide Penumbra stockholders the option to receive cash or shares of Boston Scientific common stock, with a significant portion of the payment being made in cash. The transaction is expected to close in 2026, pending necessary approvals.

In terms of financial impact, Boston Scientific anticipates that the acquisition will be dilutive to adjusted earnings per share in the first year after closing, becoming neutral or slightly accretive in the second year, and more accretive thereafter. The company plans to finance the cash portion of the deal through existing cash and new debt. Penumbra is projected to report revenue growth of approximately 21.4% to 22% for the fourth quarter and around 17.3% to 17.5% for the full year 2025, indicating a strong growth trajectory leading up to the acquisition.

Jan 15, 2026 07:21:56

Boston Scientific Approves 2026 Bonus and Performance Share Plans

Boston Scientific's Board of Directors has approved the 2026 Annual Bonus Plan, which will be effective from January 1, 2026, to December 31, 2026. This plan offers annual cash incentives based on performance metrics related to global sales, adjusted earnings per share, operating income, and corporate sustainability goals. The bonus pool is determined by the total target bonuses of participants and can vary based on the company's performance. Additionally, the plan includes provisions for recoupment of bonuses in cases of misconduct by executive officers.

The Board also approved two performance share programs for 2026: the Relative Total Shareholder Return Performance Share Program and the Organic Net Sales Growth Performance Share Program. These programs aim to align executive compensation with shareholder interests by rewarding performance based on total shareholder return compared to S&P 500 Healthcare Index companies and organic net sales growth against financial plan targets. Awards will only vest upon meeting specified performance criteria, and certain conditions apply for recoupment of performance shares in cases of executive misconduct.

Nov 19, 2025 16:20:18

Boston Scientific Director John E. Sununu Not Seeking Re-Election

John E. Sununu has announced that he will not seek re-election at Boston Scientific's 2026 Annual Meeting of Stockholders. Sununu has been a member of the Board of Directors since April 2009 and currently serves on the Audit Committee and as chair of the Nominating and Governance Committee. He will remain in his roles until the 2026 Annual Meeting.

His decision to step down is not due to any disagreement with the company. The Board and Nominating and Governance Committee will continue to assess the composition of the Board and consider the addition of new directors after Sununu's departure.

Oct 23, 2025 16:21:46

Boston Scientific Reports 20.3% Sales Growth in Q3 2025

Boston Scientific Corporation reported net sales of $5.065 billion for the third quarter of 2025, reflecting a 20.3% increase compared to the same period last year. The company's GAAP net income attributable to common stockholders was $755 million, or $0.51 per share, up from $469 million or $0.32 per share a year earlier. Adjusted earnings per share (EPS) reached $0.75, surpassing the previous year's $0.63. The sales growth exceeded the company's guidance of 17 to 19% and was driven by strong performance in the cardiovascular and MedSurg segments, with respective growth rates of 22.4% and 16.4% on a reported basis.

For the full year 2025, Boston Scientific estimates net sales growth to be around 20% on a reported basis and 15.5% on an organic basis. The company projects GAAP EPS between $1.97 and $2.01, with adjusted EPS expected to range from $3.02 to $3.04. The fourth quarter is anticipated to see reported sales growth between 14.5% and 16.5%, with organic growth between 11% and 13%. The company continues to focus on innovation and expansion in key markets, including recent acquisitions and new product approvals.

Oct 22, 2025 06:32:46

Boston Scientific Executive Vice President to Retire in 2025

Jeffrey B. Mirviss, Executive Vice President and President of Peripheral Interventions at Boston Scientific, will retire on December 1, 2025. He will continue to serve as a senior advisor until February 27, 2026, during which he will receive his current annual salary of $705,000, prorated until his retirement date.

The company plans to enter into a Retirement Agreement with Mr. Mirviss that will provide him with benefits consistent with the company’s existing retirement plans and equity awards. These arrangements will be in accordance with the terms outlined in the company's previously filed plans with the U.S. Securities and Exchange Commission.

Sep 04, 2025 16:07:43

Boston Scientific Reports Q2 2025 Financial Results and Growth

Boston Scientific Corporation reported net sales of $5.061 billion for the second quarter of 2025, reflecting a growth of 22.8% compared to the same period last year. The company achieved a GAAP net income of $797 million, or $0.53 per share, up from $324 million, or $0.22 per share, in the prior year. Adjusted earnings per share (EPS) were $0.75, exceeding prior guidance. The company noted significant sales growth in its MedSurg and Cardiovascular segments and across various regions, particularly in the U.S., which saw a 30.7% increase in reported sales. Additionally, Boston Scientific received FDA approval for new medical devices and completed several acquisitions to enhance its product offerings.

For the full year 2025, Boston Scientific anticipates net sales growth of approximately 18% to 19% on a reported basis and adjusted EPS in the range of $2.95 to $2.99. The company's guidance for the third quarter includes a projected EPS of $0.44 to $0.46 on a GAAP basis and adjusted EPS of $0.70 to $0.72. The company continues to focus on expanding its product portfolio and investing in clinical trials to drive future growth.

Jul 23, 2025 06:32:54

Boston Scientific Reports $4.561 Billion in Q4 2024 Sales

Boston Scientific Corporation announced net sales of $4.561 billion for the fourth quarter of 2024, marking a 22.4 percent increase compared to the same period last year. The company also reported a GAAP net income of $566 million, or $0.38 per share, up from $504 million or $0.34 per share a year earlier. Adjusted earnings per share rose to $0.70 from $0.55 in the previous year. Sales growth was driven by strong performance in the Cardiovascular segment, which saw a reported increase of 28.8 percent, and a notable 30.7 percent growth in the U.S. market. Additionally, the company completed several strategic acquisitions and received regulatory approvals for new products, enhancing its market position and product offerings.

Conversely, the company's GAAP net income per share fell short of its guidance range of $0.41 to $0.43. The MedSurg segment experienced slower growth, with only a 12.4 percent increase reported. Furthermore, while the overall sales growth was significant, the company faced challenges in achieving its organic sales growth targets, which were below expectations. The financial results highlighted the impact of foreign currency fluctuations and the complexities involved in integrating new acquisitions, which may influence future performance.

Feb 05, 2025 06:41:47

Boston Scientific Settles Derivative Action with Governance Reforms

Boston Scientific Corporation has reached a settlement in a shareholder derivative action, which includes adopting corporate governance reforms aimed at addressing allegations made in the case. The settlement is considered beneficial for the company and its shareholders, as it aims to resolve ongoing legal disputes and associated costs, while also enhancing governance practices within the organization.

On the downside, the settlement follows claims of wrongdoing against several executives, including allegations of breaches of fiduciary duty and misleading statements that inflated stock prices. While the defendants deny any wrongdoing, the legal proceedings and associated costs have raised concerns regarding the company's management and governance practices, leading to the necessity for reform measures as part of the settlement agreement.

Jan 16, 2025 16:26:10

Boston Scientific Welcomes David Habiger to Board of Directors

Boston Scientific has elected David Habiger to its board, bringing over 30 years of leadership experience, particularly in technology. His background includes roles at J.D. Power and other tech firms. The company’s CEO expressed enthusiasm for Habiger's insights to enhance their innovative medical solutions, signaling positive growth potential.

Jul 30, 2024 16:18:24